Dagmar Rosa-Bjorkeson
C- Suite Executive, Consultant and Board Director, Biotech
- Role
- Board of Directors, Audit Committee Member at Xencor
- Location
- Morristown, NJ, US
- LinkedIn followers
- 500 followers
About Dagmar Rosa-Bjorkeson
I am a Biopharmaceuticals Executive and Board Member, recognized for leading organizational transformations, establishing a clear vision, aligning strategy, and building the capabilities and teams that deliver effective execution. I excel at bringing a patient-centric approach and building product innovation through market development as well as driving operational clarity, alignment and structure. I lead teams across the organization to bridge silos between operations and science. Strong proponent of inclusive leadership, I motivate and mobilize teams in support of a patient-centered focus resulting in successful outcomes. Highly valued for the ability to align people and deliver launch excellence across mass markets, specialty and rare disease segments.Select Career Highlights- COO at Mesoblast, a cell technology company, to evolve from R&D to commercial stage.• Elected to the Board of Xencor, Inc in the immune-oncology space.• Built a New Products and Launch Excellence organization for Mallinckrodt.• Evolved Biosimilars Division at Baxalta to filing and market preparation of two major anti-TNFs.• Led the optimization of the post-spin Baxalta Launch Excellence capabilities.• Built Multiple Sclerosis Business Unit for Novartis U.S. to yearly revenues of $1B in three years.• Oversaw the business development and licensing department for U.S. co-promotions and licenses. • Managed Respiratory specialty franchise in U.S. market with revenues >$500M.• Managed Novartis entire portfolio as Country Head Sweden, improving profitability while restructuring.• Successfully launched a Dermatology product, exceeding expectations and surpassing 1st in class competitor share.
Experience
Board of Directors, Audit Committee Member
Dec 2019 — Present · Monrovia, CA, US
Supporting the organizational evolution to commercial stage. Xencor is a clinical-stage biopharmaceutical company (NASDAQ: XNCR) focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases.
Education
The University of Texas at Austin
Master of Science - MS, Inorganic Chemistry
1981 — 1989
Texas McCombs School of Business
Master of Business Administration - MBA, Marketing
1987 — 1989
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.